RxDoctor Payments DataLook up a doctor →

Quoc Truong, MD

Hematology & Oncology · Wichita, KSNPI 1518922814

Payments from drug & device makers

$539,217in general payments, 2019–2025

Across 2,274 payments — averaging $237.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$135K
  • Incyte Corporation$96K
  • Bristol Myers Squibb$51K
  • Johnson & Johnson$37K
  • Eisai Inc.$30K
  • Beigene USA, Inc.$21K
  • plus $167K from 54 others

What the payments were for

  • Consulting fees$76,07614%
  • Speaking & faculty fees$389,83072%
  • Travel & lodging$31,2106%
  • Food & beverage$40,0297%
  • Education$8130%
  • Other$5980%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)200$135,496
Incyte Corporation96$95,821
Bristol Myers Squibb106$51,216
Johnson & Johnson(2 entities)112$37,287
Eisai Inc.64$29,837
Beigene USA, Inc.31$21,009
Merck110$18,626
Jazz Pharmaceuticals Inc.24$16,602
Daiichi Sankyo Inc.61$16,144
AbbVie(2 entities)81$15,600
Epizyme, Inc.19$14,984
Pharmacyclics LLC, An Abbvie Company39$13,875
Regeneron Healthcare Solutions, Inc.28$11,376
CTI Biopharma Corp.14$11,332
Dova Pharmaceuticals14$8,842
E.r. Squibb & Sons, L.L.C.136$7,483
Novartis162$3,188
Pfizer116$2,841
Bayer39$2,178
Apellis Pharmaceuticals, Inc.17$2,176
Janssen Global Services, LLC1$1,980
Amgen71$1,187
Janssen Scientific Affairs, LLC1$1,170
Verastem, Inc.3$1,149
Rigel Pharmaceuticals, Inc.20$1,133
Adaptive Biotechnologies Corporation8$1,129
Sanofi40$1,023
Seagen Inc.57$946
Karyopharm Therapeutics Inc.6$864
Eagle Pharmaceuticals, Inc.1$850
Genentech USA, Inc.53$778
EMD Serono, Inc.47$721
Gilead(2 entities)42$633
Takeda Pharmaceuticals U.S.A., Inc.33$586
Verity Pharmaceuticals Inc.1$500
Puma Biotechnology, Inc.17$496
Lilly USA, LLC22$486
GSK31$479
AVEO Pharmaceuticals, Inc.11$454
Astellas Pharma US Inc29$427
Ipsen Biopharmaceuticals, Inc16$400
Array Biopharma Inc24$376
Tersera Therapeutics LLC14$332
Exelixis Inc.15$296
Genmab U.S., Inc.12$230
Servier Pharmaceuticals LLC13$225
Deciphera Pharmaceuticals Inc.7$220
Kyowa Kirin, Inc.12$211
Sobi, Inc10$210
Taiho Oncology, Inc.11$208
Clovis Oncology, Inc.6$201
Pharmaessentia USA Corporation8$181
Sun Pharmaceutical Industries Inc.10$180
Dendreon Pharmaceuticals LLC7$175
Blue Earth Diagnostics9$168
Blueprint Medicines Corporation11$163
ADC Therapeutics America, Inc.7$160
Foundation Medicine, Inc.8$147
Acrotech Biopharma Inc.7$139
Stemline Therapeutics Inc.8$139

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$539,217 in reported general payments places this provider in the 80th percentile of 97 hematology & oncology providers in Kansas.

See all hematology & oncology providers in Kansas

Medicare billing

Part B allowed, 2024
$9,024,819
Medicare patients
1,273
Services billed
416,773

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lenalidomide62$768,577
ImbruvicaIbrutinib24$392,095
IbrancePalbociclib23$335,765
BrukinsaZanubrutinib18$257,209
JakafiRuxolitinib Phosphate21$193,249
BesremiRopeginterferon Alfa-2b-Njft12$188,811
RydaptMidostaurin11$125,142
VenclextaVenetoclax13$124,870
IngrezzaValbenazine Tosylate13$118,440
LynparzaOlaparib13$110,493
EliquisApixaban51$34,346
Letrozole144$7,593
Anastrozole263$3,698
Gabapentin171$2,453
Acyclovir162$2,086

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Pharmacyclics LLC, An Abbvie CompanyImbruvica$13,875$392,09524 claims
PfizerIbrance, Eliquis$2,841$370,11174 claims
Beigene USA, Inc.Brukinsa$21,009$257,20918 claims
Incyte CorporationJakafi$95,821$193,24921 claims
Pharmaessentia USA CorporationBesremi$181$188,81112 claims
NovartisRydapt$3,188$125,14211 claims
AbbVieVenclexta$15,600$124,87013 claims
AstraZenecaLynparza$135,496$110,49313 claims
Lilly USA, LLCOlanzapine$486$64168 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 97 hematology & oncology providers in Kansas.

Other hematology & oncology in Wichita

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →